How Agentic AI Shortens Drug Development and Boosts Patient Outcomes - Ep. 277

What It Covers

IQVIA executives Raja Shankar and Avanar Broy explain how agentic AI transforms pharmaceutical development and commercialization by automating clinical trial workflows, accelerating drug launches, and connecting fragmented healthcare data across 1 billion patient records globally.

Key Questions Answered

• •Clinical Trial Automation: Agentic AI reduces clinical trial timelines by automating hundreds of manual processes including document generation, site readiness tracking, and patient enrollment monitoring, potentially saving sponsors hundreds of millions in development costs and accelerating market access by six months or more.
• •Data Connection Over Collection: Market research with 107 life sciences executives reveals 80% of time is spent stitching data together versus analyzing it. The primary challenge is not data scarcity but connecting heterogeneous data sources across behavioral, consumer, execution, and clinical datasets to generate actionable insights for drug launches.
• •Commercial Launch Strategy: Agentic AI transforms three critical phases: pre-launch strategy including patient burden analysis and payer messaging, operational planning for HCP segmentation and territory design, and engagement optimization through automated marketing channels and personalized physician outreach to reach underserved patient populations faster.
• •Implementation Framework: Successful agentic AI adoption requires four elements: start with clear business KPIs tied to strategic goals, fail quickly through rapid pilot-to-decision cycles, ensure compliant data access with sufficient metadata for model training, and design for organizational scale including change management and workforce readiness from day one.